Lee’s Pharma Obtains China Rights to Therapeutic Peptide from RegeneRx
Lee’s Pharmaceutical of Hong Kong has bought the China rights to a novel clinical-stage peptide from RegeneRx Biopharma. Thymosin beta 4 (Tβ4) is being developed by for tissue and organ protection, repair and regeneration. Its three formulations target very different indications: dry eye, cardiovascular/nervous system disorders, and skin disease/chronic wounds. More details.... Stock Symbols: (HK: 950) (OTCBB: RGRX) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here